MB076 is an innovative heterocyclic triazole designed with enhanced plasma stability. It effectively inhibits seven distinct Class C Acinetobacter-derived cephalosporinases (ADCs) β-lactamase variants with K i values less than 1 μM. Additionally, MB076 demonstrates a synergistic effect when combined with various cephalosporins to restore pBCSK(−) susceptibility [1].

MB076 (compound B) 在人血浆中表现出优异的稳定性 (0.5-5 μM, 48 h)，t 1/2 值为29 h，显著高于 ADC-7/S02030 (PDB4U0X) 的9 h。在10 μg/mL浓度下，MB076 与 Ceftazidime (CAZ)、Cefotaxime (CTX) 联合可协同恢复 pBCSK(−) 的药物敏感性。Cell Viability Assay 使用的细胞系为人血浆，浓度为0.5 μM、1 μM、2.5 μM、4 μM、5 μM，孵育时间为48小时 [1]。